Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1135-45. doi: 10.1586/14787210.2013.842466. Epub 2013 Oct 7.

Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.

Author information

1
WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia.

Abstract

Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are the most commonly used class of influenza antiviral drugs for the treatment of infected patients. In vitro studies have shown that influenza B viruses are significantly less susceptible to oseltamivir and other neuraminidase inhibitors compared with influenza A viruses. Following analysis of published clinical studies, we show that oseltamivir does appear to have lower effectiveness in patients infected with influenza B virus compared with influenza A infected patients, but due to insufficient studies on zanamivir, laninamivir or peramivir, it was not possible to conclude the relative effectiveness of these drugs against influenza A virus compared with B virus.

PMID:
24093683
DOI:
10.1586/14787210.2013.842466
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center